Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02249169 · ClinicalTrials.gov registry record
Developing Novel Microbiota-Targeted Therapies for Irritable Bowel Syndrome
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 84
- Enrollment target
NCT02249169: Completed study, sponsored by Mayo Clinic.
NCT02249169 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 84 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02249169 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 84 participants
- Enrollment target
Study Summary
This longitudinal study is being done to understand mechanisms underlying development of irritable bowel syndrome (IBS) and the role of the gut bacteria in development of symptoms. This information will be used to determine whether temporal changes in gut microbial taxonomy and metabolism are associated with changes in symptom severity in IBS, and if targeted dietary interventions, including prebiotics, can reverse or moderate these changes.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2014-09-19 |
| Est. Completion | 2017-02-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02249169
The ClinicalTrials.gov registry entry for NCT02249169 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02249169 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02249169 about?
NCT02249169 is a clinical study titled "Developing Novel Microbiota-Targeted Therapies for Irritable Bowel Syndrome". This longitudinal study is being done to understand mechanisms underlying development of irritable bowel syndrome (IBS) and the role of the gut bacteria in development of symptoms. This information will be used to determine whether temporal changes in gut microbial taxonomy and metabolism are associ...
What is the current status of trial NCT02249169?
This trial is currently completed. The enrollment target is 84 participants. The study started on 2014-09-19. Estimated completion is 2017-02-08.
Who is sponsoring clinical trial NCT02249169?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.